About Mosanna Therapeutics
Mosanna Therapeutics is a company based in Basel (Switzerland) founded in 2022 by Jonathan Talbot. Mosanna Therapeutics has raised $80 million across 3 funding rounds from investors including EQT, Norwest Venture Partners and Supermoon Capital. Mosanna Therapeutics offers products and services including MOS-118. Mosanna Therapeutics operates in a competitive market with competitors including Apnimed, Aculys, Avadel Pharmaceuticals, Circadian Therapeutics and sofi, among others.
- Headquarter Basel, Switzerland
- Founders Jonathan Talbot
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Mosanna Therapeutics Ag
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$80 M (USD)
in 3 rounds
-
Latest Funding Round
$80 M (USD), Series A
Jun 09, 2025
-
Investors
EQT
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Mosanna Therapeutics
Mosanna Therapeutics offers a comprehensive portfolio of products and services, including MOS-118.
Small molecule for treating metabolic obstructive sleep apnea.
People of Mosanna Therapeutics
Unlock access to complete
Product Management Team
1 people
Leadership Team
1 people
Consultant Team
1 people
CSO Team
1 people
Unlock access to complete
Funding Insights of Mosanna Therapeutics
Mosanna Therapeutics has successfully raised a total of $80M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $80 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Mosanna Therapeutics
Mosanna Therapeutics has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include EQT, Norwest Venture Partners and Supermoon Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is offered for sleep, health, and wellness innovations.
|
Locked | Locked | Locked | |
|
Early-stage investments are made in high-tech startups by HTGF.
|
Locked | Locked | Locked | |
|
Forty51 Ventures is focused on building early-stage biotech companies in Europe.
|
Locked | Locked | Locked |
Investor details for Mosanna Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mosanna Therapeutics
Investment portfolio details for Mosanna Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Mosanna Therapeutics
Detailed financials for Mosanna Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mosanna Therapeutics Comparisons
Peer comparison for Mosanna Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Mosanna Therapeutics
Mosanna Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Apnimed, Aculys, Avadel Pharmaceuticals, Circadian Therapeutics and sofi, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Small molecule therapeutics for obstructive sleep apnea are developed.
|
|
| Locked | Locked | Locked |
Therapeutic medicines for neuropsychiatric and sleep disorders are developed.
|
|
| Locked | Locked | Locked |
Proprietary drug delivery technologies and narcolepsy treatments are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics to treat circadian rhythm disruption
|
|
| Locked | Locked | Locked |
Provider of natural remedy based mental & physical wellbeing services
|
Detailed competitors of Mosanna Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mosanna Therapeutics
Complete news archive for Mosanna Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mosanna Therapeutics
Mosanna Therapeutics was founded in 2022.
Mosanna Therapeutics is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Jonathan Talbot is the current CEO of Mosanna Therapeutics. They have also founded this company.
Mosanna Therapeutics is a funded company, having raised a total of $80M across 3 funding rounds to date.
Mosanna Therapeutics was founded in 2022 in Basel, Switzerland, within the biotechnology sector. Small molecule therapeutics targeting sleep apnea are developed, with a focus on obstructive sleep apneas cardiometabolic effects. The lead candidate, MOS-118, is positioned as a precision medicine. Operations emphasize research and development of these compounds, led by co-founder and CEO Jonathan Talbot. The companys domain is mosanna.com.
Mosanna Therapeutics's top competitors include Apnimed, Avadel Pharmaceuticals and Aculys.
Mosanna Therapeutics offers MOS-118.
Mosanna Therapeutics has 8 investors. Key investors include EQT, Norwest Venture Partners, Supermoon Capital, High-Tech Gründerfonds, and Forty51 Ventures.